BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Fred Paster as Head of Commercial.

Fred is a seasoned healthcare industry business leader who has overseen research and business development pipelines across oncology, specialty and rare diseases to commercial success, with experience across the United States, Europe, Latin America and Asia. As the new Head of Commercial at PharmaEssentia, Fred will be responsible for the strategic growth of PharmaEssentia USA’s capabilities and collaborations to enable transformative healthcare solutions for patients with challenging diseases in the areas of hematology, oncology and immunology. In his role, Fred will lead the commercial teams, including sales, marketing and analytics.

"Fred has extensive experience at premier pharmaceutical organizations growing pipelines and overseeing products across their lifecycles, and we are thrilled to welcome him to PharmaEssentia to help drive another commercial growth and success,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and Chief Executive Officer. “This is an exciting time in our Company’s growth, as we advance our commitment to provide new therapeutic solutions for patients with myeloproliferative neoplasms and other hematological diseases that have limited therapeutic options.”

Before coming to PharmaEssentia, Fred has a proven track record as a leader in the healthcare industry with experience across the United States, Europe, Latin America, and Asia, including serving in leadership posts for Alexion Pharmaceuticals, Takeda Oncology and Takeda Pharma International. Fred also has held multiple commercial and marketing positions with Millennium Pharmaceuticals, The Medicines Company and Boston Consulting Group. Fred received his M.S. and B.S. at Massachusetts Institute of Technology and M.B.A. at Harvard Business School. He is also a Chartered Financial Analyst (CFA) charterholder.

About PharmaEssentia

PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit the website, LinkedIn or Twitter.

Forward Looking Statement

This press release may contain forward looking statements, including statements regarding the clinical benefits to be derived from ropeginterferon alfa-2b, the commercial opportunity and competitive positioning, new indications or labeling for ropeginterferon alfa-2b, and business prospects for ropeginterferon alfa-2b. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and similar legislation and regulations under Taiwanese law. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward looking statements as a result of various factors. These factors include whether BESREMi is successfully commercialized and adopted by physicians and patients, the extent to which reimbursement is available for BESREMi, and the ability to receive FDA and other regulatory approvals for additional indications for BESREMi. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

© 2024 PharmaEssentia Corporation. All rights reserved.

PharmaEssentia, the PharmaEssentia logo, and BESREMi are trademarks or registered trademarks of PharmaEssentia Corporation.

Contacts

Media:


Muriel Huang, [email protected]